Quick answer: Free testosterone peaks at approximately 300–1,000 ng/dL in healthy young men and declines 1–2% per year after age 30 — by age 70, average total testosterone is 35–40% lower than at peak, with free testosterone falling even more sharply due to rising SHBG. Functional medicine optimization addresses the full Hypothalamic-Pituitary-Gonadal (HPG) axis, not just replacement.
The HPG Axis: Why Testosterone Is a Downstream Marker
Testosterone is the end product of a sophisticated neuroendocrine cascade. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulsatile bursts every 90–120 minutes, stimulating the anterior pituitary to secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). LH acts on testicular Leydig cells to convert cholesterol → pregnenolone → DHEA → androstenedione → testosterone via the steroidogenic pathway. This cascade is exquisitely sensitive to negative feedback: rising testosterone suppresses both hypothalamic GnRH and pituitary LH, creating the regulatory loop that exogenous testosterone disrupts completely.
The bioavailability problem is central to understanding why total testosterone is an inadequate measure. Sex Hormone Binding Globulin (SHBG) — produced by the liver — binds testosterone with high affinity, rendering it biologically inactive. Albumin binds testosterone loosely and is considered “bioavailable.” Only free testosterone (approximately 2–3% of total) is fully active at the androgen receptor. Critical: SHBG rises with age, thyroid hormone, estradiol, and caloric restriction — meaning a man’s total testosterone can be “normal” while free testosterone is severely deficient. Optimal SHBG is 20–40 nmol/L; values above 60 nmol/L warrant intervention to liberate bioavailable testosterone.
The Evidence: What Low Testosterone Actually Does to the Body
The Framingham Heart Study analysis by Travison et al. (2007, Journal of Clinical Endocrinology & Metabolism) documented a population-level decline in male testosterone independent of aging — men in 2002 had testosterone levels approximately 17% lower than men of the same age in 1987, suggesting environmental and lifestyle factors beyond chronological aging. The Massachusetts Male Aging Study (n=1,709, longitudinal) found that low testosterone predicted incident metabolic syndrome, Type 2 diabetes, and cardiovascular events over 8 years of follow-up.
Mechanistically, androgen receptors are expressed in cardiac myocytes, vascular endothelium, skeletal muscle, bone, brain, and adipose tissue. Low testosterone drives: sarcopenia (loss of type II muscle fibers and satellite cell function), visceral adiposity (testosterone inhibits adipogenic differentiation and promotes lipolysis in abdominal fat), insulin resistance (Ding 2006, Diabetes Care meta-analysis: testosterone inversely correlated with insulin resistance, MetS, and T2DM), bone mineral density loss (aromatization to estradiol is actually the dominant driver of male bone density), cognitive decline (androgen receptors dense in hippocampus and prefrontal cortex, testosterone promotes BDNF and neurogenesis), and cardiovascular risk (Khaw 2007, Circulation: men in lowest quartile of endogenous testosterone had 41% higher all-cause and 38% higher cardiovascular mortality over 10 years).
Comprehensive Testing: Beyond Total Testosterone
A complete male hormonal assessment requires multiple biomarkers, drawn in the morning (7–10 AM) when testosterone is at its diurnal peak. A single low reading must be confirmed on a second test.
Tier 1 — Essential: Total testosterone (LC-MS/MS mass spectrometry preferred over immunoassay, which can overestimate at low values), Free testosterone (calculated via Vermeulen equation using SHBG and albumin, or equilibrium dialysis gold standard), LH and FSH (distinguishes primary hypogonadism — high LH/FSH with low T, testicular failure — from secondary/central — low LH/FSH with low T, HPG axis dysfunction), SHBG, Estradiol (sensitive LC-MS/MS, not standard immunoassay — men often have excessive aromatase activity converting testosterone to estradiol, causing gynecomastia, mood changes, and low T symptoms despite adequate total levels), PSA (baseline before any testosterone therapy).
Tier 2 — Functional Assessment: DHEA-S (adrenal androgen precursor, declines with age and chronic stress — Baulieu 2000 DHEA trial), Prolactin (if elevated, suggests pituitary adenoma suppressing HPG axis — must be ruled out in secondary hypogonadism), Thyroid panel (hypothyroidism increases SHBG and impairs steroidogenesis), Metabolic panel including fasting insulin and HOMA-IR (insulin resistance is bidirectional with low testosterone — each worsens the other), Cortisol (chronic hypercortisolism suppresses GnRH and LH secretion via direct hypothalamic inhibition), Complete blood count (baseline hematocrit — testosterone stimulates erythropoiesis, polycythemia is the most common adverse effect of TRT).
Lifestyle Optimization: Maximizing Endogenous Testosterone Production
Sleep architecture is the most underappreciated determinant of testosterone. Testosterone is secreted in pulses tightly coupled to sleep stages — approximately 70% of daily testosterone is produced during sleep, with the majority released during early morning REM cycles. Leproult and Van Cauter (2011, JAMA, n=10 young men, 1 week of 5-hour sleep restriction) documented a 10–15% reduction in daytime testosterone — equivalent to 10–15 years of biological aging. Stage 3 slow-wave sleep is essential for maintaining LH pulsatility. Targeting 7–9 hours nightly in a cool, dark room is non-negotiable before pursuing any hormonal intervention.
Resistance training produces acute testosterone surges and long-term elevation via multiple mechanisms: increased androgen receptor density in muscle tissue, improved insulin sensitivity (reducing the testosterone-suppressing effects of hyperinsulinemia), and direct stimulation of Leydig cell function. High-volume, multi-joint movements (squats, deadlifts, rows) with moderate loads (70–85% 1RM) and moderate rest periods (60–120 seconds) produce the greatest acute hormonal response. Craig et al. (1989, Medicine & Science in Sports & Exercise) established the exercise-induced testosterone response; subsequent work by Kraemer and Ratamess has defined the optimal protocol parameters.
Body composition optimization is critical because adipose tissue expresses aromatase (CYP19A1), which converts testosterone to estradiol. Every 1 kg of excess visceral fat increases aromatase activity, creating a self-reinforcing cycle: low testosterone → fat gain → more aromatase → lower testosterone → more fat gain. A 10% reduction in body weight in overweight men produces clinically meaningful testosterone increases averaging 25–30% (Khoo 2010, Diabetes Care). Cruciferous vegetables (broccoli, Brussels sprouts) contain indole-3-carbinol (I3C) and its metabolite DIM (diindolylmethane), which modulate estrogen metabolism toward less active 2-hydroxyestrone rather than proliferative 16α-hydroxyestrone.
Dietary factors: Dietary fat — particularly saturated and monounsaturated fats — is the substrate for steroidogenesis. Hamalainen et al. (1984, Hormone and Metabolic Research) demonstrated that men shifting from high-fat (40% calories) to low-fat (25% calories) diet had 15% reductions in testosterone. Cholesterol is the obligate precursor for all steroid hormones. Zinc deficiency directly impairs testosterone synthesis — Prasad 1996 demonstrated that dietary zinc restriction in young healthy men reduced testosterone by 75% over 20 weeks, while supplementation in elderly deficient men doubled testosterone. Magnesium is a cofactor for SHBG-binding, with deficiency correlating with lower free testosterone (Cinar 2011).
Evidence-Based Supplementation for HPG Axis Support
Ashwagandha (KSM-66 extract) has the most robust evidence for testosterone support among botanicals. Wankhede et al. (2015, Journal of the International Society of Sports Nutrition, RCT n=57, 8 weeks, 300mg KSM-66 BID): testosterone increased 15% vs. placebo, with significant improvements in muscle recovery and strength. Chauhan et al. (2022, Medicine, n=57): KSM-66 300mg BID produced 14.7% testosterone increase. The proposed mechanism involves HPA axis normalization — by reducing cortisol 27.9% (Chandrasekhar 2012), ashwagandha removes a major suppressive signal on HPG axis function, as cortisol directly inhibits GnRH pulsatility and testicular steroidogenesis via glucocorticoid receptors on Leydig cells.
Zinc and Magnesium: Combined supplementation (ZMA: 30mg zinc, 450mg magnesium aspartate, 10.5mg B6) in a Brilla and Conte (2002, Journal of Exercise Physiology) 8-week RCT of NCAA football players produced 30% higher free testosterone than placebo, with significantly greater strength gains. Zinc inhibits aromatase activity, reducing estrogen conversion. Magnesium reduces SHBG binding affinity, liberating more free testosterone. Optimal serum zinc is 80–120 μg/dL; RBC magnesium (not serum) is the preferred functional test, with optimal values 5.6–7.0 mg/dL.
Vitamin D3 functions as a steroid hormone, with androgen receptor promoter regions containing Vitamin D Response Elements. Pilz et al. (2011, Hormone and Metabolic Research, RCT n=54, 3,332 IU D3 vs. placebo, 12 months): testosterone increased 25.2% in the supplementation group vs. 2.4% in placebo. Epidemiologically, Vitamin D levels correlate with testosterone across multiple populations. Target serum 25-OH-D: 50–70 ng/mL for optimal hormonal function. Most men require 4,000–6,000 IU D3 daily with K2 (MK-7) 100–200 mcg to achieve this level safely.
Boron: Naghii et al. (2011, Journal of Trace Elements in Medicine and Biology): 10mg boron daily for 4 weeks in healthy men increased free testosterone 28.3%, decreased SHBG 9%, and reduced estradiol 39%. Boron appears to inhibit SHBG binding affinity and modulate estrogen metabolism. It is also a cofactor for Vitamin D activation and magnesium metabolism. Dietary boron is found in raisins, almonds, avocado, and legumes; supplementation of 3–10 mg/day is commonly used.
Tongkat Ali (Eurycoma longifolia, LJ100 extract): A systematic review by Leisegang et al. (2022, Andrologia): across 7 clinical trials (n=411), LJ100 supplementation consistently improved testosterone levels (mean increase ~23%), sexual function scores, and stress-related outcomes. The mechanism involves inhibition of SHBG binding via eurycomanone, LH-stimulating activity on Leydig cells, and potential 5α-reductase modulation. Studies have used 200–400mg LJ100 standardized extract.
Testosterone Replacement Therapy: Indications, Protocols, and Monitoring
TRT is indicated when total testosterone is consistently below 300 ng/dL (Endocrine Society guidelines) or when free testosterone is below the lower limit of normal with concurrent symptoms (fatigue, low libido, erectile dysfunction, loss of morning erections, decreased muscle mass, increased central adiposity, cognitive fog, depressed mood). Symptoms alone without biochemical confirmation are insufficient to initiate therapy. The 2018 AUA guidelines emphasize that prior to starting TRT, secondary causes must be excluded: pituitary adenoma (check prolactin, MRI if LH/FSH low with low T), hemochromatosis (serum ferritin, transferrin saturation), Klinefelter syndrome (47,XXY karyotype), and medications (opioids, glucocorticoids, ketoconazole, and anabolic steroids all suppress HPG axis).
Available testosterone formulations: Testosterone cypionate or enanthate (IM/subcutaneous injection) — most cost-effective, flexible dosing, produces supraphysiological peaks with troughs unless given frequently; weekly injections (100–200mg) are standard, but twice-weekly or every-5-day dosing produces more stable levels. Testosterone undecanoate (Aveed, IM every 10 weeks) — very stable levels, office-administered, expensive. Topical gels/creams — convenient, physiologic levels, risk of transference to partners/children, variable absorption (10–15% bioavailability). Pellet implants — inserted subcutaneously every 3–6 months, very stable levels. Clomiphene citrate — selectively blocks estrogen receptors at pituitary, removes negative feedback, increases endogenous LH/FSH and testosterone while preserving fertility and testicular size — preferred for men desiring future paternity.
Critical TRT monitoring: Hematocrit every 3–6 months (testosterone stimulates erythropoiesis — values above 54% require dose reduction or therapeutic phlebotomy due to polycythemia/thrombosis risk), PSA (annual after age 40, every 6 months in first year of TRT — any rise >1.4 ng/mL in 12 months or PSA >4.0 ng/mL warrants urology referral), Estradiol (sensitive assay — many men on TRT develop estrogen excess from aromatization, causing breast tenderness, water retention, mood lability, and paradoxically low libido despite high testosterone; aromatase inhibitors like anastrozole at 0.25–0.5mg 2x/week may be needed, though overtreatment of estrogen is as harmful as excess), LH/FSH (will be suppressed on exogenous TRT — confirms suppression), Testicular atrophy (predictable consequence of TRT — hCG 500–1,000 IU 2–3x/week maintains intratesticular testosterone and testicular volume while on TRT; essential for men wishing to preserve fertility or testicular function).
Testosterone and Cardiovascular Health: The Evidence
The cardiovascular safety of TRT has been subject to significant controversy. Two 2010 studies raised concerns (Basaria et al., NEJM, and a Testosterone in Older Men with Mobility Limitations trial stopped early due to cardiovascular events), but methodological issues limited interpretation. Subsequent large observational studies — including Shores et al. (2012, JCEM, n=1,032 VA patients, 3x lower mortality in testosterone-treated vs. untreated hypogonadal men) and Muraleedharan et al. (2013, European Journal of Endocrinology, n=581: treated hypogonadal men had 21% vs. 6% mortality vs. untreated) — suggested net benefit.
The landmark TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine, n=5,246, randomized controlled trial of testosterone gel vs. placebo in hypogonadal men with established cardiovascular disease or high CV risk, 33 months median follow-up) found testosterone was non-inferior to placebo for MACE (major adverse cardiovascular events): HR 0.96 (95% CI 0.78–1.17). However, TRT did increase rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (1.5% vs. 1.0%). This landmark trial provides the most rigorous safety data to date — confirming neither cardiac benefit nor harm from TRT in high-risk men, with specific signals for AF and VTE warranting monitoring.
Men’s Hormonal Health and Connection to The Private Practice
At The Private Practice, we approach testosterone optimization as a systems problem — not a simple replacement equation. The HPG axis interacts with thyroid function (see our functional thyroid medicine guide), the HPA stress axis (see our HPA axis dysregulation article), insulin resistance (see our insulin resistance guide), and sleep quality (see our sleep optimization article). A man with low testosterone who also has untreated hypothyroidism, sleep apnea, insulin resistance, and chronic stress may restore testosterone significantly through lifestyle and targeted interventions — before ever requiring exogenous therapy.
Our comprehensive male hormonal evaluation includes the full biomarker panel described above, body composition assessment, metabolic testing, and an individualized protocol prioritizing lifestyle optimization, targeted nutraceutical support, and — when clinically indicated — the most appropriate pharmaceutical approach for each patient’s goals and risk profile.
Frequently Asked Questions
What total testosterone level is considered low?
The Endocrine Society defines hypogonadism as a total testosterone below 300 ng/dL confirmed on two morning measurements. However, functional medicine practitioners recognize that the reference range (typically 300–1,000 ng/dL) is population-derived and includes unhealthy men — many men feel significant symptoms at 350–450 ng/dL, particularly if SHBG is elevated (reducing free testosterone), if estradiol is disproportionately high, or if they have androgen receptor sensitivity issues. Symptoms combined with biochemical confirmation guide treatment decisions. Free testosterone below 50–60 pg/mL (or below the lower quartile for age) is often clinically significant regardless of total testosterone. Optimal — not just “normal” — total testosterone for men seeking longevity and performance is generally 600–900 ng/dL.
Does testosterone therapy cause prostate cancer?
The historical “androgen hypothesis” proposed by Huggins and Hodges (1941) established that castration improved metastatic prostate cancer, leading to the assumption that testosterone drives prostate cancer growth. However, the “saturation model” (Morgentaler and Traish, 2009, European Urology) proposes that androgen receptors become saturated at relatively low testosterone levels (~150–200 ng/dL), meaning prostate cancer growth is not meaningfully driven by testosterone in the physiological range. Multiple large studies — including the Health Professionals Follow-Up Study — have failed to find an association between endogenous testosterone levels and prostate cancer risk. The 2018 AUA guidelines do not consider controlled hypogonadism (after adequate treatment of localized prostate cancer) an absolute contraindication to TRT. PSA monitoring remains mandatory, and active or recent prostate cancer is a contraindication until more data emerge.
Will testosterone therapy make me infertile?
Yes — exogenous testosterone strongly suppresses spermatogenesis by suppressing LH (which maintains intratesticular testosterone levels 100x higher than serum) and FSH (which drives Sertoli cell and sperm maturation). The World Health Organization studied testosterone enanthate as a male contraceptive and found 95%+ azoospermia with adequate dosing. Suppression is typically reversible — most men recover spermatogenesis 6–18 months after stopping TRT, though recovery is not guaranteed, particularly after years of use. Men wishing to preserve fertility should use clomiphene citrate (which stimulates endogenous testosterone while preserving HPG axis function) or add hCG to their TRT protocol. Sperm banking before initiating TRT is prudent for men who may desire future paternity.
What is the difference between “low T” and “andropause”?
Andropause (also termed ADAM — Androgen Deficiency in Aging Males — or “late-onset hypogonadism”) describes the gradual age-related decline in testosterone that affects a substantial minority of aging men — unlike menopause, it is not a universal phenomenon, it occurs gradually over decades rather than acutely, and levels never reach zero. Approximately 20% of men over 60 and 50% over 80 have testosterone below 300 ng/dL. “Low T” (clinical hypogonadism) can occur at any age due to primary testicular failure (Klinefelter syndrome, testicular trauma/infection, chemotherapy), secondary HPG dysfunction (pituitary tumors, opioid use, obesity-related hypogonadism, chronic illness), or the cumulative lifestyle factors of the modern environment described above. Functional medicine distinguishes age-related decline from correctable secondary dysfunction — the former may be appropriate for TRT, the latter should be treated at the root cause first.
To schedule a comprehensive male hormonal evaluation at The Private Practice, call (810) 206-1402 or visit theprivatepractice.co. We provide thorough testing, individualized protocols, and ongoing monitoring to optimize your hormonal health at every stage of life.